Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel

  • Qian Li,
  • Mei Liu,
  • Fei Ma,
  • Yang Luo,
  • Ruigang Cai,
  • Liming Wang,
  • Ningzhi Xu,
  • Binghe Xu
  • Article
  • Metrics
  • Comments
  • Media Coverage

There is an error in reference 29. The correct reference is: Mo W, Zhang J, Li X, Meng D, Gao Y, Yang S, et al. (2013) Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling through Critical Pathways to Regulate Cell Viability in Prostate Cancer. PLoS ONE 8(2): e56592.

Reference

  1. 1. Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, et al. (2014) Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. PLoS ONE 9(8): e104870. pmid:25137071

Citation: Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, et al. (2015) Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. PLoS ONE 10(8): e0136826. https://doi.org/10.1371/journal.pone.0136826

Published: August 25, 2015

Copyright: © 2015 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited